Compare MITT & RPID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MITT | RPID |
|---|---|---|
| Founded | 2011 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medical Specialities |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 231.7M | 204.3M |
| IPO Year | N/A | 2021 |
| Metric | MITT | RPID |
|---|---|---|
| Price | $7.40 | $1.96 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 1 |
| Target Price | ★ $9.25 | $8.00 |
| AVG Volume (30 Days) | ★ 182.2K | 150.5K |
| Earning Date | 04-29-2026 | 05-08-2026 |
| Dividend Yield | ★ 11.96% | N/A |
| EPS Growth | N/A | ★ 2.78 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $33,587,000.00 |
| Revenue This Year | $3.48 | $19.12 |
| Revenue Next Year | $5.06 | $18.42 |
| P/E Ratio | $9.34 | ★ N/A |
| Revenue Growth | N/A | ★ 19.74 |
| 52 Week Low | $6.81 | $1.91 |
| 52 Week High | $9.27 | $4.94 |
| Indicator | MITT | RPID |
|---|---|---|
| Relative Strength Index (RSI) | 36.59 | 30.81 |
| Support Level | $7.32 | N/A |
| Resistance Level | $7.92 | $2.46 |
| Average True Range (ATR) | 0.18 | 0.15 |
| MACD | -0.06 | -0.05 |
| Stochastic Oscillator | 9.40 | 5.00 |
TPG Mortgage Investment Trust Inc is a real estate investment trust (REIT). It focuses on investing in a diversified risk-adjusted portfolio of residential mortgage-related assets in the U.S. mortgage market. Its objective is to provide attractive risk-adjusted returns to its stockholders over the long term through dividends and capital appreciation. The company focuses on its investment activities on acquiring and securitizing newly-originated residential mortgage loans within the non-agency segment of the housing market.
Rapid Micro Biosystems Inc is an life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The company's flagship Growth Direct platform automates and modernizes the antiquated, manual microbial quality control (MQC) testing workflows used in the pharmaceutical manufacturing operations across the globe. It derives revenue from development, manufacturing, marketing and selling Systems and related LIMS connection software, consumables and services.